Therapeutic vaccines: challenges of chronic viral infections

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 4, 2007, Pages 253-266

  Sällberg, Matti ^a   Weiland, Malin ^a   Frelin, Lars ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA; DNA VACCINE; HEPATITIS B CORE ANTIGEN; HEPATITIS B CORE ANTIGEN KANAMYCIN KINASE FUSION PROTEIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HEPATITIS C VACCINE; HYBRID PROTEIN; INTERFERON; INTERLEUKIN 2; LAMIVUDINE; NONSTRUCTURAL PROTEIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GLYCOPROTEIN E1; RECOMBINANT GLYCOPROTEIN E2; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; RIBAVIRIN; T LYMPHOCYTE PEPTIDE; VIRUS DNA; VIRUS PROTEIN; VIRUS VECTOR;

CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; NONHUMAN; REVIEW; SEROCONVERSION; TREATMENT DURATION; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 46949111529     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.02.004     Document Type: Review

References (155)

1. Sherwood J. Syphilization: human experimentation in the search for a syphilis vaccine in the nineteenth century. J. Hist. Med. Allied Sci. 54 (1999) 364-386
2. Plotkin S.A. Vaccination against the major infectious diseases. C. R. Acad. Sci. III 322 (1999) 943-951
3. Bergquist G. Vaccine therapy in bronchial asthma. Acta Allergol. 9 (1955) 97-106
4. Ahlen, G. et al. (2007) In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ cells. J. Immunol. 179, 4741-4753.
5. Giri M., et al. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin. Microbiol. Rev. 17 (2004) 370-389
6. Bertoletti A., et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 10445-10449
7. Ferrari C., et al. Functional modulation of hepatitis B core antigen-specific T lymphocytes by an autoreactive T cell clone. J. Immunol. 141 (1988) 1155-1160
8. Ferrari C., et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 145 (1990) 3442-3449
9. Jung M.C., et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J. Virol. 69 (1995) 3358-3368
10. Milich D.R. Pathobiology of acute and chronic hepatitis B virus infection: an introduction. J. Viral Hepat. 4 Suppl. 2 (1997) 25-30
11. Guidotti L.G., et al. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 4589-4594
12. Guidotti L.G., et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4 (1996) 25-36
13. Penna A., et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J. Clin. Invest. 98 (1996) 1185-1194
14. Rehermann B., et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2 (1996) 1104-1108
15. Fu J., et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132 (2007) 2328-2339
16. Stoop J.N., et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41 (2005) 771-778
17. Penna A., et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25 (1997) 1022-1027
18. Farci P., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 (1992) 135-140
19. Farci P., et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 7792-7796
20. Weiner A., et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 2755-2759
21. Berkower I., et al. A possible immunodominant epitope recognized by murine T lymphocytes immune to different myoglobins. Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 4723-4727
22. Wettstein P.J. Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. II. Observation of a hierarchy among dominant antigens. Immunogenetics 24 (1986) 24-31
23. Wettstein P.J., and Bailey D.W. Immunodominance in the immune response to "multiple" histocompatibility antigens. Immunogenetics 16 (1982) 47-58
24. Diepolder H.M., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 (1995) 1006-1007
25. Missale G., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98 (1996) 706-714
26. Kamar N., et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J. Am. Soc. Nephrol. 14 (2003) 2092-2098
27. Pawlotsky J.M. Therapy of hepatitis C: from empiricism to eradication. Hepatology 43 2 Suppl. 1 (2006) S207-S220
28. Lang L. HCV findings presented at EASL: long-term follow-up and the criteria of a cure. Gastroenterology 132 (2007) 2282-2283
29. Gale Jr. M., and Foy E.M. Evasion of intracellular host defence by hepatitis C virus. Nature 436 (2005) 939-945
30. Foy E., et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300 (2003) 1145-1148
31. Li K., et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2992-2997
32. Meylan E., et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437 (2005) 1167-1172
33. Frelin L., et al. The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor {alpha} mediated liver disease. Gut 55 (2006) 1475-1483
34. Disson O., et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 126 (2004) 859-872
35. Duong F.H., et al. Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A. Gastroenterology 126 (2004) 263-277
36. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat. Rev. Drug Discov. 1 (2002) 911-916
37. Seifert U., et al. Hepatitis C virus mutation affects proteasomal epitope processing. J. Clin. Invest. 114 (2004) 250-259
38. Rehermann B., et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J. Virol. 70 (1996) 7092-7102
39. Soderholm J., et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 55 (2006) 266-274
40. Soderholm J., and Sallberg M. A complete mutational fitness map of the hepatitis C virus nonstructural 3 protease: relation to recognition by cytotoxic T lymphocytes. J. Infect. Dis. 194 (2006) 1724-1728
41. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 (2005) 946-952
42. Cox A.L., et al. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42 (2005) 104-112
43. Cox A.L., et al. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med. 201 (2005) 1741-1752
44. Lauer G.M., et al. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J. Virol. 76 (2002) 6104-6113
45. Chisari F.V. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Curr. Top. Microbiol. Immunol. 206 (1996) 149-173
46. Sette A.D., et al. Overcoming T cell tolerance to the hepatitis B virus surface antigen in hepatitis B virus-transgenic mice. J. Immunol. 166 (2001) 1389-1397
47. Chen M., et al. Immune tolerance split between hepatitis B virus precore and core proteins. J. Virol. 79 (2005) 3016-3027
48. Chen M.T., et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14913-14918
49. Milich D.R., et al. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 6599-6603
50. Rehermann B., et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J. Clin. Invest. 97 (1996) 1655-1665
51. Schirmbeck R., et al. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J. Virol. 69 (1995) 5929-5934
52. Schirmbeck R., et al. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J. Immunol. 152 (1994) 1110-1119
53. Couillin I., et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180 (1999) 15-26
54. Pol S., et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Acta Gastroenterol. Belg. 61 (1998) 228-233
55. Pol S., et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 34 (2001) 917-921
56. Davis H.L., et al. Direct gene transfer in skeletal muscle: plasmid DNA-based immunization against the hepatitis B virus surface antigen. Vaccine 12 (1994) 1503-1509
57. Davis H.L., et al. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet. 2 (1993) 1847-1851
58. Rottinghaus S.T., et al. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21 (2003) 4604-4608
59. Prince A.M., et al. Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus. Vaccine 15 (1997) 916-919
60. Shata M.T., et al. Attempted therapeutic immunization in a chimpanzee chronic HBV carrier with a high viral load. J. Med. Primatol. 35 (2006) 165-171
61. Mancini-Bourgine M., et al. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 24 (2006) 4482-4489
62. Catanzaro A.T., et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25 (2007) 4085-4092
63. Tavel J.A., et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J. Acquir. Immune Defic. Syndr. 44 (2007) 601-605
64. Graham B.S., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194 (2006) 1650-1660
65. Wolff J.A., and Budker V. The mechanism of naked DNA uptake and expression. Adv. Genet. 54 (2005) 3-20
66. Zhang G., et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther. 11 (2004) 675-682
67. Davis H.L., et al. DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 7213-7218
68. Sallberg M., et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum. Gene Ther. 9 (1998) 1719-1729
69. Lai C.L., and Yuen M.F. Profound suppression of hepatitis B virus replication with lamivudine. J. Med. Virol. 61 (2000) 367-373
70. Lazdina U., et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J. Gen. Virol. 84 Pt 1 (2003) 139-146
71. Lazdina U., et al. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells. J. Virol. 75 (2001) 6367-6374
72. Milich D.R., et al. Role of B cells in antigen presentation of the hepatitis B core. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 14648-14653
73. Riedl P., et al. Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J. Immunol. 168 (2002) 4951-4959
74. Billaud J.N., et al. Combinatorial approach to hepadnavirus-like particle vaccine design. J. Virol. 79 (2005) 13656-13666
75. Billaud J.N., et al. Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms. Vaccine 25 (2007) 1593-1606
76. Sallberg M., et al. A malaria vaccine candidate based on a hepatitis B virus core platform. Intervirology 45 (2002) 350-361
77. Nardin E.H., et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun. 72 (2004) 6519-6527
78. Oliveira G.A., et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 73 (2005) 3587-3597
79. Kuhober A., et al. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J. Immunol. 156 (1996) 3687-3695
80. Sallberg M., et al. Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens. J. Virol. 71 (1997) 5295-5303
81. Townsend K., et al. Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens. J. Virol. 71 (1997) 3365-3374
82. Fuller D.H., et al. Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques. Virology 364 (2007) 245-255
83. Ruedl C., et al. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur. J. Immunol. 32 (2002) 818-825
84. Huang Z., et al. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 24 (2006) 2506-2513
85. Li H., et al. Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments. J. Immunol. 174 (2005) 195-204
86. Heathcote J., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30 (1999) 531-536
87. Garcia-Navarro R., et al. Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J. Virol. 75 (2001) 9068-9076
88. Menne S., et al. Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J. Virol. 71 (1997) 65-74
89. Schodel F., et al. Immunization with recombinant woodchuck hepatitis virus nucleocapsid antigen or hepatitis B virus nucleocapsid antigen protects woodchucks from woodchuck hepatitis virus infection. Vaccine 11 (1993) 624-628
90. Lu M., et al. Immunization of woodchucks with plasmids expressing woodchuck hepatitis virus (WHV) core antigen and surface antigen suppresses WHV infection. J. Virol. 73 (1999) 281-289
91. Miller D.S., et al. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner. Virology 351 (2006) 159-169
92. Triyatni M., et al. Protective efficacy of DNA vaccines against duck hepatitis B virus infection. J. Virol. 72 (1998) 84-94
93. Foster W.K., et al. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob. Agents Chemother. 47 (2003) 2624-2635
94. Guidotti L.G., et al. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69 (1995) 6158-6169
95. Milich D.R., et al. Extrathymic expression of the intracellular hepatitis B core antigen results in T cell tolerance in transgenic mice. J. Immunol. 152 (1994) 455-466
96. Lerat H., et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122 (2002) 352-365
97. Moriya K., et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4 (1998) 1065-1067
98. Ahlen G., et al. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J. Infect. Dis. 192 (2005) 2112-2116
99. Yang P.L., et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13825-13830
100. Zhang G., et al. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10 (1999) 1735-1737
101. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
102. Day C.L., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
103. Kakimi K., et al. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 76 (2002) 8609-8620
104. Lindenbach B.D., et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3805-3809
105. Mercer D.F., et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7 (2001) 927-933
106. Meuleman P., et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41 (2005) 847-856
107. Law M., et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14 (2007) 25-27
108. Grakoui A., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003) 659-662
109. Shoukry N.H., et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197 (2003) 1645-1655
110. Kaplan D.E., et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132 (2007) 654-666
111. Bjoro K., et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N. Engl. J. Med. 331 (1994) 1607-1611
112. von Hahn T., et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132 (2007) 667-678
113. Zhang P., et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8449-8454
114. Ralston R., et al. Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J. Virol. 67 (1993) 6753-6761
115. Choo Q.L., et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1294-1298
116. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 (2005) 961-966
117. Gordon E.J., et al. Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations. J. Infect. Dis. 181 (2000) 42-50
118. Koshy R., and Inchauspe G. Evaluation of hepatitis C virus protein epitopes for vaccine development. Trends Biotechnol. 14 (1996) 364-369
119. Lagging L.M., et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J. Virol. 69 (1995) 5859-5863
120. Sallberg M., et al. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus non-structural 3 protein. J. Gen. Virol. 77 Pt 11 (1996) 2721-2728
121. Tokushige K., et al. Expression and immune response to hepatitis C virus core DNA-based vaccine constructs. Hepatology 24 (1996) 14-20
122. Zhang Z.X., et al. Immune responses to the hepatitis C virus NS4A protein are profoundly influenced by the combination of the viral genotype and the host major histocompatibility complex. J. Gen. Virol. 78 Pt 11 (1997) 2735-2746
123. Encke J., et al. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J. Immunol. 161 (1998) 4917-4923
124. Geissler M., et al. Differential cellular and humoral immune responses to HCV core and HBV envelope proteins after genetic immunizations using chimeric constructs. Vaccine 16 (1998) 857-867
125. Inchauspe G., et al. Immune responses against hepatitis C virus structural proteins following genetic immunisation. Dev. Biol. Stand. 92 (1998) 163-168
126. Lazdina U., et al. Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein. J. Gen. Virol. 82 Pt 6 (2001) 1299-1308
127. Major M.E., et al. DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J. Virol. 69 (1995) 5798-5805
128. Pancholi P., et al. DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J. Virol. 77 (2003) 382-390
129. Brinster C., et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 83 Pt 2 (2002) 369-381
130. Brinster C., et al. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 34 (2001) 1206-1217
131. Frelin L., et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther. 11 (2004) 522-533
132. Frelin L., et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther. 10 (2003) 686-699
133. Capone S., et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J. Immunol. 177 (2006) 7462-7471
134. Folgori A., et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12 (2006) 190-197
135. Pala P., et al. Competition between unrelated peptides recognized by H-2-Kd restricted T cells. J. Immunol. 141 (1988) 2289-2294
136. Palmowski M.J., et al. Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J. Immunol. 168 (2002) 4391-4398
137. Hinkula J., et al. Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses. Vaccine 15 (1997) 874-878
138. Cheng G., et al. Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9035-9040
139. Fournillier A., et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 25 (2007) 7339-7353
140. Vona G., et al. Intrahepatic hepatitis C virus RNA quantification in microdissected hepatocytes. J. Hepatol. 40 (2004) 682-688
141. Boni C., et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest. 102 (1998) 968-975
142. Maier H., et al. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J. Immunol. 178 (2007) 2714-2720
143. Urbani S., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80 (2006) 11398-11403
144. Urbani S., et al. Heterologous T cell immunity in severe hepatitis C virus infection. J. Exp. Med. 201 (2005) 675-680
145. Horiike N., et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J. Clin. Virol. 32 2 (2005) 156-161
146. Helvaci M., et al. Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B. J. Gastroenterol. Hepatol. 19 7 (2004) 785-791
147. Yalcin K., et al. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection 31 4 (2003) 221-225
148. Yalcin K., et al. The lack of effect of therapeutic vaccination with a pre-S2/S HBV vaccine in the immune tolerant phase of chronic HBV infection. J. Clin. Gastroenterol. 37 4 (2003) 330-335
149. Jung M.C., et al. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20 29-30 (2002) 3598-3612
150. Dahmen A., et al. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J. Med. Virol. 66 4 (2002) 452-460
151. Pol S., et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J. Hepatol. 34 6 (2001) 917-921
152. Couillin I., et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180 1 (1999) 15-26
153. Nevens F., et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38 5 (2003) 1289-1296
154. Firbas C., et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24 20 (2006) 4343-4353
155. Leroux-Roels G., et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22 23-24 (2004) 3080-3086